By decreasing Medicare’s contribution to branded Part D drugs, the act can make generic drugs cheaper for plans — even after manufacturer rebates
Market Access
Product Development
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
Regulation
No black box warning and a broad label for the pediatric brain cancer therapy
Deals
Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programs
Management Tracks
Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech
BioCentury ISSN 1097-7201